Antares signs licensing deal with Daewoong for Oxybutynin Gel 3%

Antares oxybutynin gel 3% is a topical, translucent hydroalcoholic gel containing oxybutynin, an antispasmodic, antimuscarinic agent and is indicated for the treatment of (OAB).

The FDA approved oxybutynin product is available in a metered-dose pump that has demonstrated to be an effective and safe treatment for OAB.

The active ingredient in the product is delivered transdermally, and is therefore not metabolized by the liver in the same way as orally administered oxybutynin.

Under the licensing deal, Antares will receive upfront payments, regulatory milestones and sales based milestones, as well as royalties on net sales for the product.